Treatment of Stenotrophomonas maltophilia UTI in Bactrim-Allergic Catheterized Patient
For this 87-year-old catheterized patient with confirmed S. maltophilia UTI who cannot receive trimethoprim-sulfamethoxazole, use levofloxacin 750 mg daily for 7-10 days as first-line monotherapy, with catheter replacement if it has been in place ≥2 weeks.
Immediate Management Steps
Catheter Management
- Replace the catheter immediately if it has been in place for ≥2 weeks at infection onset, as this hastens symptom resolution and reduces recurrence risk 1
- Obtain urine culture from the freshly placed catheter before starting antibiotics 1
- Remove the catheter entirely if no longer medically necessary
Antimicrobial Selection
Primary recommendation: Levofloxacin monotherapy
- Dose: 750 mg once daily (IV or oral)
- Duration: 7 days for prompt symptom resolution; extend to 10-14 days if delayed response 1
- Rationale: Levofloxacin shows 78.9% susceptibility against S. maltophilia in recent U.S. surveillance data 2, and the 750 mg dose specifically demonstrated efficacy in catheterized patients with complicated UTI 1
Alternative options if levofloxacin resistance or contraindication:
Minocycline 100 mg twice daily
Cefiderocol 2 g IV every 8 hours
- Emerging option with excellent activity 4
- Reserve for severe cases or multi-drug resistant isolates
Critical Considerations for This Patient
Age-Related Factors
At 87 years old, this patient has increased mortality risk from catheter-associated bacteremia (approximately 10%) 5. Monitor closely for:
- Fever, rigors, altered mental status
- Flank pain or costovertebral angle tenderness
- Hemodynamic instability
Combination Therapy Decision
Monotherapy is appropriate for this patient unless they present with:
- Septic shock
- Immunocompromised state
- Bacteremia (not just cystitis)
Recent evidence shows no significant benefit of combination therapy over monotherapy for S. maltophilia infections (clinical failure 47.1% vs 36.0%, not statistically significant), with higher adverse event rates in combination therapy groups 6. The IDSA recommendation for combination therapy is based on limited data and may increase toxicity without clear benefit 6.
If Combination Therapy Needed
Based on mortality data, cefoperazone-sulbactam plus levofloxacin showed better outcomes than monotherapy in severely ill patients 7. However, cefoperazone-sulbactam availability is limited in the U.S., making this less practical.
Treatment Duration Algorithm
7 days: Patient afebrile within 48 hours, symptoms resolving, hemodynamically stable 5
10-14 days:
- Delayed fever resolution (>48 hours)
- Male patient (cannot exclude prostatitis) 5
- Persistent symptoms
- Immunocompromised status
Common Pitfalls to Avoid
Do NOT use fluoroquinolones empirically if the patient has received them in the past 6 months—resistance risk is substantially higher 5
Do NOT use moxifloxacin for UTI treatment despite its activity against S. maltophilia—urinary concentrations are inadequate 1
Do NOT continue the old catheter if it has been in place ≥2 weeks—biofilm formation prevents adequate antimicrobial penetration 1
Do NOT assume susceptibility—S. maltophilia resistance to levofloxacin can reach 21% in some centers 2. Adjust therapy based on culture results.
Monitor for levofloxacin resistance development—this occurs most commonly among fluoroquinolones with S. maltophilia 6
Monitoring and Follow-Up
- Obtain susceptibility testing results and adjust therapy accordingly
- If no clinical improvement within 48-72 hours, consider:
- Repeat urine culture
- Alternative diagnosis (obstruction, abscess)
- Resistance development
- Switch to minocycline or combination therapy
The evidence strongly supports that catheter replacement combined with appropriate monotherapy achieves optimal outcomes for most catheter-associated S. maltophilia UTIs 1, avoiding unnecessary toxicity from combination regimens while maintaining efficacy.